Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 2Phase 3 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Recurrence 3Hematologic Neoplasms 3Melanoma 2Lymphoma, Non-Hodgkin 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Solid Tumors Harboring NTRK Fusion 1Skin Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neuroblastoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mesothelioma, Malignant 1Mastocytosis, Systemic 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Locally Advanced Solid Tumors 1Leukemia, Myeloid, Acute 1Leukemia, Mast-Cell 1Head and Neck Neoplasms 1Glioma 1Gastrointestinal Stromal Tumors 1Endometrial Neoplasms 1Diffuse Intrinsic Pontine Glioma 1

Interventions

Crizotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Has announcements × Neuroblastoma × Clear all
NCT01121588 2025-01-23

Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)

Pfizer

Phase 1 Terminated
44 enrolled 22 charts 1 FDA
CNSLymphoid

Lymphoma, Neoplasms, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡